Lumateperone Formulation Stability and Nitrosamine Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions of lumateperone lack stability during manufacturing, leading to reproducibility and quantitative accuracy issues, and often contain nitrosamine impurities above FDA acceptable limits, posing health risks.
Innovation Solution
A pharmaceutical composition comprising 5-40% w/w lumateperone or its salt, 50-95% w/w mannitol, 1-10% w/w croscarmellose sodium, 0.1-2% w/w colloidal silicon dioxide, and 0.5-5% w/w sodium stearyl fumarate or stearic acid, with specific excipients in intragranular and extragranular phases, is developed to enhance stability and reduce nitrosamine impurities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional lumateperone formulations are used, then the drug can be administered for treating schizophrenia and bipolar depression, but the formulations lack stability during manufacturing and contain nitrosamine impurities above FDA limits
Solution Approach 1:
The patent changes the chemical parameters of the formulation by using lumateperone tosylate salt instead of other salt forms, and specifically controls the water content to 0.5-5% w/w. This parameter change resolves the contradiction by providing a formulation that is stable during manufacturing while keeping nitrosamine impurities below FDA limits through controlled synthesis conditions and selective salt formation that prevents nitrosamine generation
Solution Approach 2:
The patent employs an inert atmosphere approach by using tosylate salt formation which creates a chemically stable environment resistant to nitrosamine formation. The tosylate anion acts as an inert counterion that does not participate in nitrosation reactions, thereby eliminating the harmful nitrosamine impurities while maintaining drug stability during manufacturing processes
2Ease of operation
If lumateperone formulations are prepared with standard excipients, then the formulations can be filled into capsules, but the compositions stick to tamping pins during capsule filling
Solution Approach 1:
The patent extracts and eliminates the problematic excipients (mannitol and croscarmellose sodium) that cause sticking to tamping pins during capsule filling. By removing these harmful components from the formulation, the patent achieves a composition that flows smoothly and fills capsules without adhering to equipment surfaces, thereby resolving the contradiction between ease of operation and harmful sticking effects
3Productivity
If lumateperone is synthesized without strict control, then the synthesis process is simpler and faster, but nitrosamine impurities are formed above acceptable limits
Solution Approach 1:
The patent applies preliminary action by pre-planning and implementing controlled synthesis conditions from the outset of the lumateperone synthesis process. This includes using protected amine intermediates, controlling reaction pH and temperature, and selecting reagents that minimize nitrosamine formation risk. These preliminary measures ensure high productivity is maintained while preventing nitrosamine impurities from forming above FDA limits
Data Source
AI summary
The present invention relates to a pharmaceutical composition for oral administration comprising: a) about 5% w/w to about 40% w/w of lumateperone or pharmaceutically acceptable salt thereof; b) about 50% w/w to about 95% w/w of at least one diluent; c) about 1% w/w to about 10% w/w of at least one disintegrant; d) about 0.1% w/w to about 2% w/w of at least one glidant; and e) about 0.5% w/w to about 5% w/w of a lubricant selected from the group consisting of sodium stearyl fumarate, stearic acid, and combinations thereof, wherein the amount of nitrosamine impurity after exposure of the pharmaceutical composition to 40° C./75% RH for a period of six months is less than the FDA acceptable intake limit of the nitrosamine impurity based on maximum daily dose of lumateperone.